Local recurrence after primary therapy for clinically localized prostate cancer: Is radiation or surgery “Better” in the salvage setting?

2008 ◽  
Vol 97 (5) ◽  
pp. 376-376
Author(s):  
Christopher G. Wood
Keyword(s):  
Prostate Cancer ◽  
Local Recurrence ◽  
Localized Prostate Cancer ◽  
Primary Therapy

Do Seminal or Prostatic Secretions Play a Role in Local Recurrence after Radical Prostatectomy for Localized Prostate Cancer?

1993 ◽  
Vol 24 (4) ◽  
pp. 471-473 ◽  
Author(s):  
Antoine S. Abi Aad ◽  
Henri Noél ◽  
Francis Lorge ◽  
François X. Wese ◽  
Reinier J. Opsomer ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Local Recurrence ◽  
Localized Prostate Cancer

scholarly journals Simultaneous integrated boost with stereotactic radiotherapy for dominant intraprostatic lesion of localized prostate cancer: a dosimetric planning study

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Yeon Joo Kim ◽  
Kyoung Jun Yoon ◽  
Young Seok Kim
Keyword(s):  
Prostate Cancer ◽  
Local Recurrence ◽  
Cancer Patients ◽  
Dose Escalation ◽  
Simultaneous Integrated Boost ◽  
Localized Prostate Cancer ◽  
Moderate Dose ◽  
Planning Study ◽  
Normal Organ ◽  
Integrated Boost

Abstract Dominant intraprostatic lesion (DIL) has been known as the most common local recurrence site of prostate cancer. We evaluated the feasibility of simultaneous integrated boost (SIB) to DIL with CyberKnife stereotactic body radiotherapy (CK-SBRT). We selected 15 patients with prostate cancer and visible DIL and compared 3 plans for each patient: 1) No boost plan of 35 Gy to prostate, 2) DIL_40 plan of SIB 40 Gy to DIL and 35 Gy to prostate, and 3) DIL_45 plan with 45 Gy to DIL and 35 Gy to the prostate in 5 fractions. All targets satisfied with the prescription coverage per protocol. However, some patients failed to meet the Dmax of the rectum in DIL_40 plans (n = 4), and DIL_45 plans (n = 6). Violations of bladder constraints occurred in four DIL_45 plans. Consequently, the DIL boost with SBRT was possible in 73% of patients with DIL_40 plans, and 60% of patients with DIL_45 plans without any violation of normal organ constraints. All patients who experienced constraint violations had DILs in posterior segments. DIL boost using CK-SBRT could be an option for localized prostate cancer patients. For patients who had DIL in posterior segments, a moderate dose escalation of 40 Gy seemed appropriate.

scholarly journals Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer

2016 ◽  
Vol 34 (12) ◽  
pp. 1611-1619 ◽  
Author(s):  
Alex Z. Fu ◽  
Huei-Ting Tsai ◽  
Reina Haque ◽  
Marianne Ulcickas Yood ◽  
Stephen K. Van Den Eeden ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Androgen Deprivation Therapy ◽  
Salvage Treatment ◽  
Androgen Deprivation ◽  
Localized Prostate Cancer ◽  
Primary Therapy

Prognostic significance of perineural invasion in localized prostate cancer.

2015 ◽  
Vol 33 (7_suppl) ◽  
pp. 30-30
Author(s):  
Louis Lu ◽  
Udit Singhal ◽  
Ted A. Skolarus ◽  
Ganesh S. Palapattu ◽  
Jeffrey Scott Montgomery ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Perineural Invasion ◽  
Prognostic Significance ◽  
Localized Prostate Cancer ◽  
Primary Therapy ◽  
Newly Diagnosed ◽  
Free Survival ◽  
Psa Recurrence

30 Background: While perineural invasion (PNI) has been associated with poorer clinical outcomes in prostate cancer patients, it is not well defined as a predictor of long-term endpoints in newly diagnosed prostate cancer. Therefore, we evaluated the role of PNI as a prognostic marker in patients with localized prostate cancer who underwent surgery or radiation. Methods: We analyzed a prospectively collected cohort of 5,034 consecutive patients with localized prostate cancer treated with surgery (n = 4,207) or radiation (n = 827) at University of Michigan from 1994-2013. The primary outcome measured was metastasis-free survival, with secondary outcomes of PSA-recurrence free survival and overall survival (OS). Covariates included age, treatment year, race, comorbidity index, pre-treatment PSA, Gleason score, and T-stage. Survival analysis was estimated using the Kaplan-Meir method, and multivariable analysis was performed using a Cox proportional hazards model. Results: 22.6% of surgery patients and 37.5% of radiation patients had PNI. 169 patients developed metastasis a median of 44 months (IQR 21-83 months) after primary therapy. In the combined cohort, PNI was a predictor of metastasis and PSA recurrence, but not OS (Table 1). For surgery, PNI was a predictor of metastasis, PSA recurrence, and OS. For radiation, PNI was a predictor of metastasis and PSA recurrence, but not OS. Conclusions: PNI is an independent predictor of long-term outcomes in newly diagnosed prostate cancer patients regardless of subsequent therapy. These data support the importance of PNI as a key factor denoting potentially aggressive prostate cancer and importing a significant increase in the likelihood of eventual metastatic progression. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document